Modeling Disease Progression and Rosiglitazone Intervention in Type 2 Diabetic Goto-Kakizaki Rats
暂无分享,去创建一个
[1] A. Dorrance,et al. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. , 2005, Diabetes.
[2] C. Semenkovich. TZDs and diabetes: testing the waters , 2005, Nature Medicine.
[3] F. Howarth,et al. Long‐term effects of type 2 diabetes mellitus on heart rhythm in the Goto–Kakizaki rat , 2008, Experimental physiology.
[4] Robert V Farese,et al. Thiazolidinedione Treatment Enhances Insulin Effects on Protein Kinase C-ζ/λ Activation and Glucose Transport in Adipocytes of Nondiabetic and Goto-Kakizaki Type II Diabetic Rats* , 2000, The Journal of Biological Chemistry.
[5] M. S. Santos,et al. Effects of hyperglycemia on sperm and testicular cells of Goto-Kakizaki and streptozotocin-treated rat models for diabetes. , 2006, Theriogenology.
[6] J. Vasselli,et al. Prolonged Decrease of Adipocyte Size after Rosiglitazone Treatment in High‐ and Low‐Fat‐Fed Rats , 2007, Obesity.
[7] S. Keam,et al. Rosiglitazone , 2012, Drugs.
[8] S. E. Rankin,et al. Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys. , 2004, Metabolism: clinical and experimental.
[9] M. Sasaki,et al. Development of diabetes in the non-obese NIDDM rat (GK rat). , 1988, Advances in experimental medicine and biology.
[10] D. DuBois,et al. Mechanism-Based Modeling of Nutritional and Leptin Influences on Growth in Normal and Type 2 Diabetic Rats , 2009, Journal of Pharmacology and Experimental Therapeutics.
[11] M. Matsuda,et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients , 2001, Diabetologia.
[12] K. Tsuda,et al. Long-term therapeutic effects of voglibose, a potent intestinal alpha-glucosidase inhibitor, in spontaneous diabetic GK rats. , 2003, Diabetes research and clinical practice.
[13] C. Bailey,et al. Oral antidiabetic agents: current role in type 2 diabetes mellitus. , 2005, Drugs.
[14] Wei Gao,et al. Mechanism-based disease progression modeling of type 2 diabetes in Goto-Kakizaki rats , 2011, Journal of Pharmacokinetics and Pharmacodynamics.
[15] M. Matsuda,et al. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. , 2002, Diabetes care.
[16] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[17] Jin Y. Jin,et al. Pharmacodynamics of glucose regulation by methylprednisolone. II. normal rats , 2009, Biopharmaceutics & drug disposition.
[18] D. DuBois,et al. Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. , 2008, Journal of pharmaceutical sciences.
[19] K. Shimada,et al. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. , 2003, American journal of physiology. Endocrinology and metabolism.
[20] William J Jusko,et al. Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[21] William J Jusko,et al. Modeling the metabolic effects of terbutaline in β2‐adrenergic receptor diplotypes , 2004, Clinical pharmacology and therapeutics.
[22] J. Nolan,et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus , 2000, Diabetic medicine : a journal of the British Diabetic Association.
[23] William J Jusko,et al. Pharmacodynamics of glucose regulation by methylprednisolone. I. Adrenalectomized rats , 2009, Biopharmaceutics & drug disposition.
[24] M. Sajan,et al. Rosiglitazone, Insulin Treatment, and Fasting Correct Defective Activation of Protein Kinase C-ζ/λ by Insulin in Vastus Lateralis Muscles and Adipocytes of Diabetic Rats. , 2001, Endocrinology.
[25] N. Hollenberg. Considerations for management of fluid dynamic issues associated with thiazolidinediones. , 2003, The American journal of medicine.
[26] Ronald Gieschke,et al. An Integrated Model for Glucose and Insulin Regulation in Healthy Volunteers and Type 2 Diabetic Patients Following Intravenous Glucose Provocations , 2007, Journal of clinical pharmacology.
[27] K. Tsuda,et al. Morphological changes and increased sucrase and isomaltase activity in small intestines of insulin-deficient and type 2 diabetic rats. , 2003, Endocrine journal.
[28] W. Winter,et al. A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus , 2006, Journal of Pharmacokinetics and Pharmacodynamics.
[29] C. Lister,et al. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat , 2000, Diabetes, obesity & metabolism.
[30] James H. Brown,et al. A general model for ontogenetic growth , 2001, Nature.
[31] X. Cai,et al. Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone. , 2000, Brain research. Molecular brain research.
[32] A. Saltiel,et al. Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. , 1997, Metabolism: clinical and experimental.
[33] H. Pijl,et al. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. , 2003, Metabolism: clinical and experimental.
[34] B. Zinman,et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.